TIL

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
木曜日, 5月 9, 2024
Breast cancer, FDA, Cancer, SCCA, Paclitaxel, FOLFIRINOX, International, Pancreatic cancer, Research, Thought, Immunotherapy, Breast, TSX, PR, AB, Conference, ONC, ASCO, TIL, Anal canal, Patient, Society, Pancreatic Cancer Action Network, Anal, Ethics, Annual general meeting, Pelareorep, Type, Anal cancer, CGMP, Medical imaging

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31, 2024.
  • General and administrative expenses for the first quarter of 2024 were $3.0 million, compared to $3.2 million for the first quarter of 2023.
  • Research and development expenses for the first quarter of 2024 were $5.7 million, compared to $3.5 million for the first quarter of 2023.
  • The net loss for the first quarter of 2024 was $6.9 million, compared to a net loss of $6.4 million for the first quarter of 2023.

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
木曜日, 5月 9, 2024
Momentum, IOV, Epidemiology, FDA, Investment, Lung cancer, Intellectual property, Research, National Cancer Institute, Units of paper quantity, ASCO, Endometrial cancer, TIL, Death, Cancer, Food, Second generation, Food and Drug Administration, Safety, Poster, Uterine cancer, PD-1, Next Generation, Melanoma, Marketing, Clinical trial, Investigational New Drug, Cohort, MMR, Information, Patient, Society, Interim, Growth, Pharmaceutical industry

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates. 

Key Points: 
  • Launch Following U.S. Food and Drug Administration (FDA) Approval
    SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates.
  • Iovance remains on track to onboard approximately 50 ATCs by the end of May 2024 and expects to have more than 70 ATCs onboarded by the end of 2024.
  • In the first quarter of 2024, Iovance completed the transfer of marketing authorizations and began distribution of Proleukin.
  • Beginning in the second quarter of 2024, Iovance expects to recognize significant incremental revenues for Proleukin as part of the Amtagvi treatment regimen.

Epsilon Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 5月 8, 2024
Permian, NRI, Central Time, Investment, News, Natural gas, TILS, MMBTU, Conference, Webcast, PDP, TIL, Acquisition, Interest, Cubic foot, Oil

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.

Key Points: 
  • Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.
  • In addition, our operating partner in PA curtailed production in response to low realized gas prices in the first quarter (quantified above).
  • The Company will host a conference call to discuss its results on Thursday, May 9, 2024 at 9:30 a.m. Central Time (10:30 a.m. Eastern Time).
  • Participants should ask to be joined to the “Epsilon Energy First Quarter 2024 Earnings Conference Call.”
    A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BtayVC7k .

Vital Energy Reports First-Quarter 2024 Financial and Operating Results

Retrieved on: 
水曜日, 5月 8, 2024
LOE, Vitalism, Investment, Delaware Basin, Vital, Webcast, TIL, MBO, Consolidated, OK, LTIP, GAAP

TULSA, OK, May 08, 2024 (GLOBE NEWSWIRE) -- Vital Energy, Inc. (NYSE: VTLE) ("Vital Energy" or the "Company") today reported first-quarter 2024 financial and operating results.

Key Points: 
  • TULSA, OK, May 08, 2024 (GLOBE NEWSWIRE) -- Vital Energy, Inc. (NYSE: VTLE) ("Vital Energy" or the "Company") today reported first-quarter 2024 financial and operating results.
  • "We continued our trend of delivering strong financial and operational results while successfully integrating recent acquisitions," stated Jason Pigott, President and Chief Executive Officer.
  • Results in the Southern Delaware position we built last year are far exceeding industry results.
  • During the second quarter of 2024, Vital Energy plans to operate four drilling rigs and two completions crews, and TIL 24 wells.

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Retrieved on: 
月曜日, 5月 6, 2024
Lyell, Triple-negative breast cancer, Colorectal cancer, Research, IND, TIL, Patient, NR4A3, Workforce, Memory, AACR, NSCLC, TNBC, GAAP, G&A, Lung cancer, Pharmaceutical industry

Initial data from at least 20 patients from the Phase 1 clinical trial of LYL797 are expected this quarter.

Key Points: 
  • Initial data from at least 20 patients from the Phase 1 clinical trial of LYL797 are expected this quarter.
  • Initial clinical and translational data from the Phase 1 trial of LYL845 are expected in the second half of 2024.
  • Research and development (R&D) expenses were $43.2 million for the first quarter ended March 31, 2024, compared to $44.6 million for the same period in 2023.
  • The decrease in first quarter 2024 non-GAAP R&D expenses was primarily driven by a decrease in personnel-related expenses.

Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

Retrieved on: 
水曜日, 5月 8, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Obsidian, Boston University, Chemical engineering, TIL, Senior, Chemistry, CMC, Therapy, Thermo Fisher Scientific

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.

Key Points: 
  • Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.
  • “Dana has over two decades of operational expertise across cell therapy, gene therapy and biologics process development and chemistry, manufacturing, and controls (CMC), from Phase 1 through commercialization,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian.
  • We are delighted to welcome Dana to our management team.”
    “I am thrilled to be joining the highly accomplished and passionate Obsidian leadership team and to have the opportunity to grow and expand the company’s CMC capabilities,” said Mr. Alexander.
  • Previously, Mr. Alexander held roles as Vice President of Operations, Viral Vector Services at Thermo Fisher Scientific (Brammer Bio) and Chief Operations Officer at Anika Therapeutics.

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

Retrieved on: 
火曜日, 5月 7, 2024
Learning, Quality control, Exosome, MD, Partnership, Cell, CDMO, TIL, Biotechnology, Patient, Gene, Society, Health, TCR, Annual general meeting, NK, CGMP, Pharmaceutical industry

THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

Key Points: 
  • THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
  • The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
  • Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
  • "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

Retrieved on: 
火曜日, 5月 7, 2024
Learning, Quality control, Exosome, MD, Partnership, Cell, CDMO, TIL, Biotechnology, Patient, Gene, Society, Health, TCR, Annual general meeting, NK, CGMP, Pharmaceutical industry

THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

Key Points: 
  • THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
  • The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
  • Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
  • "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.

Civitas Resources Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 2, 2024
Oil, Gas, Energy, Permian, Acquisition, Natural gas, NGL, TIL, TILS, Civitas

As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.

Key Points: 
  • As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.
  • “This quarter was the first reporting period that all our new businesses were together, and our results highlight just the beginning of Civitas' bright future ahead.
  • Sales volume for the first quarter 2024 were higher than expected at 336 MBoe/d, which benefited from continued strong well performance and accelerated turn-in-line ("TIL") timing.
  • NGL realizations per barrel represented 29% of West Texas Intermediate crude oil in the first quarter of 2024.

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

Retrieved on: 
水曜日, 4月 24, 2024
IOV, Cancer, Safety, Pembrolizumab, Webcast, McCormick Place, ASCO, TIL, Iovance Biotherapeutics, Patient, Melanoma, SAN, Vaccine

SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, will be highlighted at the upcoming 2024 ASCO Annual Meeting to be held May 31- June 4, 2024, at McCormick Place in Chicago, IL and online.

Key Points: 
  • SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, will be highlighted at the upcoming 2024 ASCO Annual Meeting to be held May 31- June 4, 2024, at McCormick Place in Chicago, IL and online.
  • Oral Presentation: Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A (Abstract 9505)
    Poster: IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens (Abstract 2552)
    Iovance will host an event on the evening of Friday, May 31, 2024 to summarize the data highlights at ASCO.
  • The live and archived event webcast will be available in the Investors section of the company’s website at www.iovance.com.